Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ARGENX BV

Home Clinical Trial Sponsors and OrganizationsARGENX BV

ARGENX BV

ACTIVE

Utländsk Adr - Foreign Addr, SwedenSubsidiary

Part of argenx SE

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

145

115 active

Approvals

4

Total approvals

Agencies

2

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

114

78.6%

Phase 3

11

7.6%

Phase 2

4

2.8%

Trial Status Distribution

Active, not recruiting

110

75.9%

Completed

10

6.9%

Not yet recruiting

5

3.5%

Recruiting

19

13.1%

Withdrawn

1

0.7%

Clinical Trials

Trials sponsored by this organization (145)

A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy

Active, not recruiting

Aug 2024240 participants

A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy

A Prospective Longitudinal Study in Adult Patients With Multifocal Motor Neuropathy (iMMersioN)

Active, not recruiting

Apr 20246 participants

A phase 3 study to evaluate the long-term safety, tolerability and efficacy of efgartigimod PH20 SC in adult participants with bullous pemphigoid. (BALLAD+)

Active, not recruiting

Feb 202412 participants

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy.

Sep 20231 participant

A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid (BALLAD)

May 202312 participants

A phase 3 study to evaluate the long-term safety, tolerability and efficacy of efgartigimod PH20 SC in adult participants with bullous pemphigoid

Jan 2023160 participants

A phase 3 study to evaluate the long-term safety, tolerability and efficacy of efgartigimod PH20 SC in adult participants with bullous pemphigoid

Jan 2023160 participants

Page 1 of 19

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

2

Approvals

CANADA

Health Canada

2

Approvals

Recent Approvals

Efgartigimod Alfa Injection (Subcutaneous Injection)

Efgartigimod Alfa Injection

News

No news articles found

On this page

Overview
Clinical Trials145
Approvals4
News

Back to Organizations